FDA advisory panel to consider approving fourth COVID-19 vaccine, this one from Maryland's Novavax
USA TodayJUL 2022
Vaccine conspiracy theories tragically stigmatized mRNA jabs for millions of people in America. An "old school" protein-based jab, similar to the flu shot, could have more appeal to the unvaccinated. US officials bet the farm on mRNA products, and it's wise to offer consumers alternatives.
Novavax is a latecomer to the COVID vaccine landscape, and its early production fumbles were costly. The market is already well established by Pfizer and Moderna in the US, and whether its non-mRNA formula will be accepted by entrenched vaccine skeptics remains very much to be seen.